Venenum Biodesign LLC has reported new substituted phenylsulfonamides acting as 2-acylglycerol O-acyltransferase 2 (MOGAT2) inhibitors described as potentially useful for the treatment of metabolic dysfunction-associated steatotic liver disease (MASLD; NAFLD) and obesity.

Shenzhen Salubris Pharmaceuticals Co. Ltd. has discovered new proprotein convertase subtilisin/kexin-type 9 (PCSK9) and 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase dual inhibitors. They are described as potentially useful for the treatment of hypercholesterolemia.

The United Bio-Technology (Hengqin) Co. Ltd. has reported compounds acting as glucagon-like peptide 1 receptor (GLP-1R) agonists. They are reported to be useful for the treatment of diabetes type 1, gout, psoriasis, stroke, inflammatory bowel disease, hyperlipidemia, and Alzheimer’s and Parkinson’s disease, among others.

Krabbe disease, also called globoid-cell leukodystrophy, is caused by a deficiency of the lysosomal enzyme β-galactosylceramidase (GALC), resulting from pathogenic variants in both copies of the GALC gene. The GALC deficiency leads to increased levels of the primary galactosphingolipid substrates, galactosylceramide (GalCer) and psychosine (galactosylsphingosine, PSY), in the nervous system.

Boehringer Ingelheim Pharma GmbH & Co. KG has synthesized peptide-lipid drug conjugates comprising a neuromedin U NMU2 receptor agonist peptide. They are reported to be useful for the treatment of obesity.

Astrazeneca AB has identified new quinazoline derivatives acting as gastric inhibitory polypeptide receptor (GIPR) antagonists. As such, they are described as potentially useful for the treatment of colitis, diabetes, inflammatory bowel disease, osteoporosis, psoriasis, schizophrenia, thrombosis and Alzheimer’s disease among others.